Tumor Burden in Sentinel Node May Help Stratify High- and Low-risk Vulvar Cancer Patients (06/15/2010)
Tumor burden in the sentinel node of early-stage vulvar cancer patients appears to be an important prognostic factor. Patients with sentinel-node metastasis larger than 2mm may have a worse prognosis.

Gardasil® Approved for Prevention of Vaginal and Vulvar Cancers (09/15/2008)
The United States Food and Drug Administration (FDA) has expanded the indication for Gardasil® (Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) for the prevention of cancers of the vagina and vulva.

Updates in the Management of Gynecologic Cancers (05/27/2008)
A Report from the 39^th Annual Meeting of the Society of Gynecologic Oncologists

Aldara™ Effective Alternative to Surgery for Precancerous Changes to Vulva (04/11/2008)
A recently published study in the New England Journal of Medicine reports that topical Aldara™ (imiquimod) may be an effective alternative to surgery for the treatment of precancerous changes to the vulva called vulvar intraepithelial neoplasia.

Gardasil® Reduces Risk of Precancerous Changes to Vagina and Vulva (05/21/2007)
According to the results of a study published in The Lancet, use of Gardasil®—a vaccine against four types of human papillomavirus—may reduce the risk of cancers of the vagina and vulva in addition to reducing the risk of cervical cancer.

Gardasil® also Likely to Prevent Most Vaginal and Vulvar Cancers (06/13/2006)
According to results presented at the 2006 annual meeting of the American Society of Clinical Oncology, Gardasil®—a recently approved vaccine intended to prevent cervical cancer, precancerous genital changes, and genital warts caused by specific types of human papillomavirus (HPV)—reduces the risk of high-grade precancerous changes to the vulva and vagina.

General

Tumor Burden in Sentinel Node May Help Stratify High- and Low-risk Vulvar Cancer Patients (06/15/2010)
Tumor burden in the sentinel node of early-stage vulvar cancer patients appears to be an important prognostic factor. Patients with sentinel-node metastasis larger than 2mm may have a worse prognosis.